These studies showed an objective response rate of 72% with a median progression-free survival of 19.2 months of NSCLC patients treated with crizotinib with high ROS1 levels and resulted in further therapeutic options of multi-targeted treatment for CCA (18). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.